Associated Papers
Frequent EPHA2 receptor mutations in cholangiocarcinoma disrupt receptor forward signaling supporting a tumor suppressor role.
Koutouan E et al.
Biochimica Et Biophysica Acta. Molecular Cell Research, 2026
Frequent EPHA2 receptor mutations in cholangiocarcinoma disrupt receptor forward signaling supporting a tumor suppressor role.
Koutouan E et al.
Biorxiv : the Preprint Server for Biology, 2025
Comparative genomic analysis unveiling the mutational landscape associated with premalignant lesions and early-stage gastric cardia cancer.
Wang G et al.
Medicine, 2025
Driver mutations of intrahepatic cholangiocarcinoma shape clinically relevant genomic clusters with distinct molecular features and therapeutic vulnerabilities.
Wang XY et al.
Theranostics, 2022
34987644 (PubMed )
Supplement: thnov12p0260s1.pdf
Mutated EPHA2 is a target for combating lymphatic metastasis in intrahepatic cholangiocarcinoma.
Sheng Y et al.
International Journal of Cancer, 2019
Germ-line and somatic EPHA2 coding variants in lens aging and cataract.
Bennett TM et al.
Plos One, 2017
29267365 (PubMed )
Supplement: pone.0189881.s004.xlsx › S4a._Clear__1__all
Increased burden of ultra-rare protein-altering variants among 4,877 individuals with schizophrenia.
Genovese G et al.
Nature Neuroscience, 2016
27694994 (PubMed )
Supplement: NIHMS815183-supplement-supp_table3.xlsx › Supplemenary_Table_3
Select a paper to view details